Proprietary due diligence that uncovers hidden risks in genomic data companies — before you sign. We combine data science, regulatory expertise, and financial forensics so you never inherit a surprise.
Every ValeBorne engagement is structured around four interlocking audit dimensions. No pillar is optional — each one has caught deal-breaking risks the others would have missed.
IP ownership verification, FDA/EMA regulatory posture, HIPAA/GDPR data privacy, and freedom-to-operate analysis before you commit capital.
Data quality (>10,000 sample threshold, >85% reproducibility), infrastructure scalability, API stability, and complete provenance tracking.
Burn rate and runway modeling, revenue quality scrutiny, customer concentration, churn, and forensic accounting ratios beyond standard review.
Team turnover and key-person dependency, process maturity (SOPs, QC), vendor and supply chain concentration, scalability signals.
From rapid 3-day red flag audits to comprehensive 10-day deep dives, with portfolio and partnership pricing for multi-deal acquirers.
Choose the depth of analysis that matches your deal stage and timeline.
Commission a single pillar — Legal, Technical/IP, Financial Health, or Operational Risk — as a standalone deliverable. Purchase individually.
Rapid full-spectrum risk assessment across every pillar. Identify deal-breakers before committing further diligence resources.
Full-spectrum analysis with integration risk modeling, scenario planning, and renegotiation leverage before you sign.
Volume pricing for VCs and PE firms managing multiple genomic data deals.
Basic four-pillar risk screening with a standard report. Ideal for initial pipeline screening across multiple targets.
Enhanced analysis with customized recommendations tailored to your investment thesis and portfolio strategy.
Full deep diligence with integration risk modeling and ongoing consultation throughout the deal lifecycle.
For high-volume acquirers — bundled RFAs and DDDs at negotiated rates.
10 Red Flag Audits + 5 Deep Due Diligence engagements. Ideal for active PE firms running 3–5 genomic deals per year.
15 Red Flag Audits + 10 Deep Due Diligence engagements. For strategic acquirers running 6–10+ deals annually.
We are so confident in our Red Flag Audit that if you are not satisfied with the depth and clarity of our findings, we will work with you to make it right — including a partial credit toward future work.
A free, focused PDF written for VC and PE partners evaluating their next genomic data acquisition. We've distilled the most common — and most expensive — risk categories we encounter, with concrete examples of how each one has derailed real deals.
Sent immediately to your inbox. No follow-up sequence unless you ask.
A briefing for deal teams evaluating genomic data acquisitions.
We offer every prospective client a free demo risk assessment on a target of their choice. Tell us about your deal and we'll prepare a focused conversation tailored to it.
A 15-minute discovery call where we walk you through our methodology and scope the right engagement for your timeline.
If you have a target in mind, we'll prepare a preliminary high-level scan beforehand so the conversation is grounded in real data — not generic talking points.
Skip the form and grab a 15-minute slot on our calendar.
Schedule on CalendlyPeriodic briefings from our team on the realities of genomic M&A — what we see, what surprises acquirers, and what we'd do differently.
A PE firm was 48 hours from signing when our Red Flag Audit surfaced a customer concentration issue and a patent expiry that reshaped the entire valuation.
Request the full case study →The five risk categories we most often see acquirers miss — and how each one has materially changed a deal we've worked.
Download the briefing →What the reproducibility crisis means for acquirers — and the validation checks every deal team should run before signing.
Coming soon →